The Dexcom G7 continuous glucose monitoring (CGM) system has been granted a CE Mark (Conformité Européenne), which means it is approved for use in people with diabetes in Europe aged 2 years and older, including pregnant women.
Compared with the Dexcom G6, the G7 has several new features that should make it easier to use, including a 60% smaller size, an all-in-one sensor with transmitter rather than the current separate devices, and a 30-minute warm-up, compared to 2 hours with the G6. The G7 also gives users a 12-hour grace period after sensor expiration to start a new one before it stops working, whereas the G6 provides no such leeway.
The mobile app reader has been redesigned and simplified to integrate with the Dexcom Clarity app, and there are more options for alert customization. The optional separate receiver is also smaller and more lightweight compared with the G5/G6 receiver. In addition, the G7 is indicated for upper arm or lower abdomen wear, in contrast to the abdomen only with the G6.
As with the G6, the G7 does not require fingersticks for calibration or dosing decisions, and glucose data can be shared with up to 10 followers. The accuracy of the G7 is as good as or better than that of other currently marketed CGMs, as reported by Medscape Medical News.
“With enhanced features and added simplicity, Dexcom G7 will hopefully make diabetes management easier for both patients and their healthcare providers, something that is especially important as we see more and more evidence of the benefits of CGM in broader populations of those living with diabetes,” said Partha S. Kar, MBBS, OBE, national specialty advisor, Diabetes at NHS England and consultant endocrinologist at Portsmouth Hospitals NHS Trust, UK, in a statement.
Dexcom is also working with insulin pump manufacturers to integrate the G7 into current and future automated insulin delivery systems.
The company expects to launch the Dexcom G7 in Europe in the next several weeks and to introduce an updated CGM algorithm later in 2022. The G7 is currently under review by the US Food and Drug Administration.
Miriam E. Tucker is a freelance journalist based in the Washington, DC, area. She is a regular contributor to Medscape, with other work appearing in The Washington Post, NPR’s Shots blog, and Diabetes Forecast magazine. She is on Twitter: @MiriamETucker.
For more diabetes and endocrinology news, follow us on Twitter and Facebook.
Source: Read Full Article